Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing.…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European…
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,” “HEMP” or the “Company”), a…
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio…
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on…
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on…
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global…
Portable, Travel-Friendly Device That Includes Everything You Need For On-The-Go Red Light Therapy. All Neatly Packed Into A Compact 12-Inch…